Documents

A list of downloadable documents created during development.

Prostate cancer (hormone-refractory) - docetaxel: Consultee and commentator comments on the ACD

Prostate cancer (hormone-refractory) - docetaxel: Expert comments on the ACD

Response to consultee, commentator and public comments on the ACD

Prostate cancer (hormone refractory) - docetaxel (appraisal consultation)

Prostate cancer (hormone-refractory) - docetaxel: overview

Prostate cancer (hormone-refractory) - docetaxel - Assessment report addendum

Prostate cancer (hormone-refractory) - docetaxel: assessment report

Prostate cancer (hormone-refractory) - docetaxel: Consultee and commentator comment on the assessment report

Prostate cancer (hormone-refractory) - docetaxel: non manufacturer submissions

Prostate cancer (hormone-refractory) - docetaxel: manufacturer submissions (executive summary only)

Prostate cancer (hormone-refractory) - docetaxel: Final protocol

Prostate cancer (hormone-refractory) - docetaxel: Final scope

Prostate cancer (hormone-refractory) - docetaxel: Summary of consultee and commentator comments of the draft scope

Prostate cancer (hormone-refractory) - docetaxel: Summary of consultee and commentator comments on the draft matrix

Prostate cancer (hormone-refractory) - docetaxel: draft scope

Prostate cancer (hormone-refractory) - docetaxel: provisional matrix of consultees and commentators

2004/027 NICE asked to develop guidance on the care of drug misuse, medicines for prostate cancer, and management of attention deficit hyperactivity disorder